Flavii Therapeutics aims to develop innovative epigenetic therapies for central nervous system disorders. To date, we have identified five promising epigenetic drugs in various stages of preclinical development, with FLAV-27 being the most advanced, now on the verge of entering regulatory preclinical studies.
THERAPEUTIC FOCUS
Flavii is committed to the preclinical and clinical development of groundbreaking epigenetic therapies aimed at addressing neurodegenerative and neurodevelopmental disorders.
ABOUT ALZHEIMER
AD is a progressive neurodegenerative condition that causes memory loss, confusion, and severe cognitive decline. It is the most common form of dementia, affecting approximately 5–7% of people aged 65 and older.
OUR SCIENTIFIC APPROACH
Epigenetic mechanisms, which regulate gene expression without altering the underlying DNA sequence, are increasingly recognized for their potential to modulate disease pathways in ways that conventional therapies cannot.
Pipeline
At Flavii, our focus is the development of innovative epigenetic therapies designed to improve outcomes for patients with CNS conditions.
Invest in the future of CNS therapies to improve patient lives
JOIN US IN REVOLUTIONIZING CNS DOSIRDERS CARE!
At Flavii, we’re pioneering epigenetic therapies to improve outcomes for patients with CNS disorders. Together, we can unlock new treatment opportunities, improving patients’ quality of life and advancing our understanding of brain disorders.
Get involved. Partner with us. Make a Difference!
Partner with us to accelerate innovation in epigenetics and CNS Therapies
RELIED UPON BY TOP RESEARCH INSTITUTIONS ACROSS THE GLOBE.
Select scientific publications from Flavii employees, founders and collaborators:
At Flavii, we are committed to making epigenetic treatments available for patients suffering from CNS disorders. We strongly believe we can succeed in meaningfully improving the lives of patients and their families.
More information
We thank our sponsors and partners for their supposd and trust in our work
